OneChain Immunotherapeutics

What OneChain Immunotherapeutics does

OneChain Immunotherapeutics is a clinical-stage biotechnology company founded in June 2020 in Barcelona as a spin-off from the Josep Carreras Leukemia Research Institute and ICREA, built around Dr. Pablo Menéndez's CAR-T research program. The company designs and develops Chimeric Antigen Receptor T-cell (CAR-T) therapies for oncological diseases, with five distinct programs spanning hematologic malignancies and solid tumors: OC-1 (CAR CD1a for cortical T-ALL, currently in Phase 1 with FDA and EMA Orphan Drug Designations), OC-1d (dual CD1a/CCR9 CAR-T targeting ~80% of T-ALL), OC-2 (CAR CD22 for B-ALL), OC-3 (an allogeneic Vδ1 gamma-delta T-cell platform enabling off-the-shelf dosing), and OC-4 (dual CAR-T for glioblastoma multiforme). The company is also participating in the TransMisiones consortium to develop an in vivo CAR-T platform using AI-designed viral particles and a separate strategic collaboration with NanoCell Therapeutics to apply its proprietary CD22 CAR construct to NanoCell's non-viral in vivo platform.

The business model is a clinical-stage biotech commercial model with no current product revenue. The company is funded through venture capital (€3.05M seed in 2020, €6.7M pre-Series A in 2023 from Invivo Capital, Nara Capital, and Clave Capital) and a mix of Spanish and European public grants totaling at least €5.7M. Future revenue mechanics will rely on out-licensing, co-development partnerships, or direct commercialization of approved CAR-T therapies, which typically command $400K-$500K+ per patient in the US/EU. The go-to-market motion is physician-led and hospital-based: patients are enrolled through clinical trial sites — currently Hospital Clínic Barcelona and Hospital Sant Joan de Déu for the CARxALL Phase 1 trial. Customers, once commercialized, will be fragmented across hematology and oncology treatment centers globally, with the addressable market concentrated in patients with relapsed/refractory disease where existing therapies have limited efficacy.

The company operates with approximately 20 team members across research, clinical operations, and administration at its corporate office on Carrer Muntaner in Barcelona and laboratories at the Barcelona Science Park. Leadership transitioned in early 2024 with Stefanos Theoharis appointed CEO, and the Board of Directors is chaired by Barbara Krebs-Pohl (appointed June 2025), a former MorphoSys CBO. Major institutional stakeholders include Invivo Capital, the Josep Carreras Leukemia Foundation, Nara Capital, Clave Capital, and public bodies (CDTI, EIC, Spanish Ministry of Science).

Name

OneChain Immunotherapeutics

Legal name

ONE CHAIN IMMUNOTHERAPEUTICS

Website

https://onechaintx.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

OneChain Immunotherapeutics is a clinical-stage Barcelona biotech developing CAR-T immunotherapies for leukemia and solid tumors, with a Phase 1 CD1a-targeted therapy for cortical T-ALL holding dual FDA/EMA Orphan Drug Designations.

Ownership category

akta.pro rank

Product category

CAR-T Cell Therapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Developers (Allogeneic/Off-the-shelf) (HLAAABAB), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK)

Keywords

• CAR-T therapy
• Cell immunotherapy
• Leukemia treatment
• Cancer biologics
• Allogeneic cell therapy

Headquarters

HQ city

Barcelona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. CAR-T Therapy Development & Commercialization: As a clinical-stage biotech, OneChain does not yet generate product revenue. The company is funded through venture capital, public grants, and will eventually seek to commercialize its CAR-T pipeline through licensing agreements, co-development partnerships, or direct commercialization upon regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

OneChain Immunotherapeutics is a clinical-stage biotechnology company developing a pipeline of CAR-T cell immunotherapies targeting oncological diseases, with a primary focus on acute lymphoblastic leukemias (T-ALL and B-ALL) and glioblastoma multiforme. The company develops autologous and allogeneic CAR-T therapies including OC-1 (CD1a-targeted, currently in Phase 1 clinical trials), dual-targeting OC-1d (CD1a/CCR9), OC-2 (CD22), an allogeneic Vδ1 γδ T cell platform (OC-3), and a dual CAR-T for glioblastoma (OC-4), along with a next-generation in vivo CAR-T platform.

Product overview

OneChain Immunotherapeutics is a clinical-stage biotechnology company developing a pipeline of CAR T-cell immunotherapies for hematological malignancies and solid tumors. The core portfolio includes OC-1 (CAR CD1a), a Phase 1 clinical-stage therapy for cortical T-ALL with EMA/FDA Orphan Drug Designation; OC-1d (dual CD1a/CCR9 CAR-T) for broader T-ALL coverage (~80% of patients); OC-2 (CAR CD22) for B-ALL; an allogeneic Vδ1 gamma-delta T cell platform (OC-3) providing off-the-shelf treatments; and a dual CAR-T for glioblastoma (OC-4). The company is also developing an in vivo CAR-T platform to enable direct in-body CAR-T engineering without ex vivo cell extraction. Founded in 2020 as a spin-off from the Josep Carreras Leukemia Research Institute and ICREA, based at the Barcelona Science Park.

Differentiator

Problem solved

Functional benefit

Products and services

• OC-1 (CAR CD1a) CAR T-cell therapy targeting the CD1a antigen for the treatment of refractory/relapsed cortical T-cell acute lymphoblastic leukemia (coT-ALL), representing 30-40% of all T-ALL cases. Currently in Phase 1 clinical evaluation (CARxALL trial, NCT05679895). Has received Orphan Drug Designation from both EMA and FDA for acute lymphoblastic leukemia.
• OC-1d (Dual CD1a/CCR9 CAR-T) Dual CAR T-cell therapy simultaneously targeting CD1a and CCR9 antigens for relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL). Designed to expand treatment eligibility to approximately 80% of T-ALL patients and reduce immune escape risk by distributing immune pressure across two antigens. In preclinical development.
• OC-2 (CAR CD22) Bispecific CAR-T therapy targeting CD22 for treatment of B-cell acute lymphoblastic leukemia (B-ALL). Positioned as an alternative to salvage chemotherapy for relapsed/refractory B-ALL patients who are not eligible for autologous stem cell transplant. Based on the proprietary CD22 CAR molecule developed by Dr. Pablo Menéndez's team and licensed to NanoCell Therapeutics for in vivo CAR-T application in B-cell lymphoma.
• OC-3 (Allogeneic Vδ1 γδ T Cell Platform) Allogeneic platform for selective, large-scale generation of human cytotoxic Vδ1+ gamma-delta T cells for adoptive cell therapy of cancer. Enables off-the-shelf (ready-to-use) CAR-T treatments at lower cost than current autologous CAR-T therapies. Supported by the European Innovation Council.
• OC-4 (Dual CAR-T for Glioblastoma) Dual CAR-T cell strategy targeting IL13a2/OC-4.2-expressing glioblastoma multiforme (GBM) tumor cells and a key component of the immunosuppressive tumor microenvironment. In preclinical development for this highly aggressive primary brain tumor with fatal prognosis and 5-year survival between 6% and 27%.
• In Vivo CAR-T Platform Next-generation in vivo CAR-T platform enabling direct in-body engineering of multiple immune cell types without ex vivo manufacturing or apheresis. Being developed jointly with NanoCell Therapeutics (non-viral DNA-based platform) and as part of the TransMisiones AI-powered consortium designing targeted viral particles for in vivo delivery.

Quantifiable outcome

• OC-1 can treat 30-40% of T-ALL patients (coT-ALL subset), while OC-1d dual CAR-T expands coverage to approximately 80% of T-ALL patients.
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Eleven partnerships are on record, tiered major, core and supporting.

• NanoCell TherapeuticsmajorStrategic or Co-development Partner · 16 May 2024Strategic collaboration to develop in vivo CAR-T therapy for B-cell lymphoma combining OneChain's proprietary CD22 CAR technology with NanoCell's non-viral, DNA-based in vivo CAR-T platform. OneChain's CD22 CAR was developed by Dr. Pablo Menéndez. NanoCell has locations in Wayne, PA (USA) and Utrecht, Netherlands.
• Josep Carreras Leukemia Research InstitutecoreStrategic or Co-development PartnerParent research institute and co-founder of OneChain Immunotherapeutics. The company was spun off from this institute in June 2020 based on research led by Dr. Pablo Menéndez's team. The institute continues as a core research collaborator on all pipeline programs.
• ICREA (Catalan Institution for Research and Advanced Studies)coreStrategic or Co-development PartnerCo-founder of OneChain Immunotherapeutics along with the Josep Carreras Institute and Dr. Pablo Menéndez. Dr. Pablo Menéndez holds an ICREA Research Professor position.
• Hospital Clínic BarcelonacoreStrategic or Co-development PartnerPrincipal investigator site for the CARxALL Phase 1 clinical trial. Under direction of Dr. Núria Martínez as principal investigator. First patient treated at this site on May 7, 2024.
• Hospital Sant Joan de DéucoreStrategic or Co-development PartnerPrincipal investigator site for the CARxALL Phase 1 clinical trial. Under direction of Dr. Susana Rives as principal investigator. Site open to both pediatric and adult patients.
• VIVEbiotechmajorStrategic or Co-development PartnerSan Sebastián-based company specializing in development and manufacture of lentiviral vectors. Lead partner in the TransMisiones consortium (€3.8M grant, 2024-2027) alongside OneChain, Integra Therapeutics, UPF, IBMB-CSIC, and CIEMAT for designing AI-driven next-generation viral particles for in vivo CAR-T therapy.
• Integra TherapeuticsmajorStrategic or Co-development PartnerBarcelona-based biotech developing gene writing tools. Partner in the TransMisiones consortium working on AI applications for protein and DNA sequence design for next-generation viral particles used in CAR-T and advanced therapies.
• UPF (Pompeu Fabra University)majorStrategic or Co-development PartnerDepartment of Medicine and Life Sciences (MELIS) at UPF, led by Dr. Marc Güell, contributes the Translational Synthetic Biology Laboratory to the TransMisiones consortium. Applying AI with directed evolution techniques to optimize viral particle targeting and delivery.
• IBMB-CSIC (Institute of Molecular Biology of Barcelona)majorStrategic or Co-development PartnerInstitute of the Spanish National Research Council (CSIC) at the Barcelona Science Park. Dr. Noelia Ferruz's group on Artificial Intelligence for Protein Design contributes language models to generate proteins with customizable properties for the TransMisiones project.
• CIEMAT (Center for Energy, Environmental and Technological Research)majorStrategic or Co-development PartnerPublic research organization attached to the Spanish Ministry of Science. Dr. José-Carlos Segovia's group at CIEMAT focuses on gene therapy and gene editing tools for genetic modification of hematopoietic stem cells, contributing to the TransMisiones project.
• Banc de Sang i Teixits (BST)supportingStrategic or Co-development PartnerBlood and Tissue Bank collaborating with OneChain and the Josep Carreras Institute on the €1.9M Ministry of Science grant project to advance CAR T therapy for T-ALL into clinical phase.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Allogene Therapeutics: Clinical-stage biotech developing allogeneic CAR-T therapies for hematologic cancers. Comparable to OneChain's OC-3 allogeneic Vδ1 γδ T-cell platform and broader CAR-T pipeline approach.
• Caribou Biosciences: Clinical-stage company developing allogeneic CAR-T cell therapies using CRISPR gene editing. Relevant comparable for OneChain's allogeneic platform and gene editing-adjacent cell therapy development.
• Cellectis: Clinical-stage biotech developing gene-edited allogeneic CAR-T therapies (UCART). Comparable due to similar allogeneic platform approach and T-ALL/B-ALL pipeline focus.
• Wugen: Clinical-stage company developing allogeneic memory NK and T-cell therapies for hematologic malignancies including T-ALL. Direct comparable for OneChain's T-ALL focus and allogeneic cell therapy approach.
• Crispr Therapeutics: Clinical-stage gene-editing biotech with CAR-T programs for hematologic cancers. Comparable to OneChain's gene-edited CAR-T and in vivo CAR-T platform development.
• Adaptimmune: Clinical-stage biotech developing engineered T-cell therapies (SPEAR T-cells) for solid and hematologic tumors. Comparable as a small-cap cell therapy company with similar clinical-stage profile.
• Precision BioSciences: Clinical-stage biotech developing allogeneic CAR-T therapies using ARCUS gene editing. Comparable for allogeneic platform development and hematologic cancer pipeline.

Emerging players

• Century Therapeutics: Early clinical-stage biotech developing iPSC-derived allogeneic cell therapies. Emerging player with similar allogeneic approach and hematologic cancer focus.

Broad incumbents

• Gilead Sciences (Kite Pharma): Large pharma with leading CAR-T franchise (Yescarta, Tecartus) covering B-cell lymphomas and ALL. Broad incumbent for the commercial CAR-T market OneChain eventually targets.
• Novartis: Large pharma with Kymriah, the first FDA-approved CAR-T therapy. Broad incumbent for CAR-T commercial market and potential acquirer of OneChain's platform technologies.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/onechaintx
• LinkedInlinkedin.com/company/onechain-immunotherapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneChain Immunotherapeutics